Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Ye, Y., Pang, Z., Chen, W., Ju, S. & Zhou, C. The epidemiology and risk factors of inflammatory bowel disease. International journal of clinical and experimental medicine 8, 22529–22542 (2015).
2. Degagne, E. & Saba, J. D. S1pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. Clinical and experimental gastroenterology 7, 205–214,
https://doi.org/10.2147/CEG.S43453
(2014).
3. Danese, S., Furfaro, F. & Vetrano, S. Targeting S1P in Inflammatory bowel disease: new avenues for modulating intestinal leukocyte migration. Journal of Crohn’s & colitis.
https://doi.org/10.1093/ecco-jcc/jjx107
(2017).
4. Peyrin-Biroulet, L., Christopher, R., Behan, D. & Lassen, C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmunity reviews 16, 495–503,
https://doi.org/10.1016/j.autrev.2017.03.007
(2017).
5. Pulkoski-Gross, M. J. et al. Novel sphingosine kinase-1 inhibitor, LCL351, reduces immune responses in murine DSS-induced colitis. Prostaglandins & other lipid mediators 130, 47–56,
https://doi.org/10.1016/j.prostaglandins.2017.03.006
(2017).
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献